| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC2545 | Hif-in-33 | Novel HIF Pathway Inhibitor |
|
| DCC2546 | Himbacine | Natural muscarinic receptor antagonist |
|
| DCC2547 | Hipk1/2-in-a64 | Novel Potent Inhibitor of HIPK1/HIPK2 Kinase |
|
| DCC2548 | Hippeastrine Hydrobromide | Natural alkaloid, demonstrating significant cytotoxicity against a panel of human and murine tumor cell lines |
|
| DCC2549 | Histidine-proline | Allosteric inhibitor of ATP phosphoribosyltransferase (ATPPRT), binding to the ATPPRT:ATP complex via a two-step binding mechanism, inhibiting ATPPRT competitively and likely uncompetitively, respectively, against PRPP and ATP |
|
| DCC2550 | Histidyl-histidine | Novel enhancer of catalytic efficiency of neurolysin |
|
| DCC2551 | Histidyltyrosine | Novel enhancer of catalytic efficiency of neurolysin |
|
| DCC2552 | Hiv-1 In Photoprobe | Novel photoaffinity-labeled probe for full-length human immunodeficiency virus-1 integrase (HIV-1 IN) |
|
| DCC2553 | Hiv-1 Inhibitor 9d | Novel highly potent HIV-1 inhibitor with broad-spectrum activity (EC50 = 2.0-57 nM) against resistant strains, exhibiting good solubility and safety profiles and a good PK profile with an oral bioavailability of 59% in rats |
|
| DCC2554 | hjc0122 | AMPA Receptor Positive Allosteric Modulator |
|
| DCC2555 | Hjc0123 | Novel orally bioavailable STAT3 inhibitor |
|
| DCC2556 | Hjc0149 | Novel potent orally bioavailable inhibitor of signal transducer and activator of transcription 3 (STAT3) |
|
| DCC2557 | Hjc05100 | Novel apigenin analogue, suppressing pancreatic stellate cell proliferation |
|
| DCC2558 | Hk Inhibitor 2 | Novel inhibitor of YycG histidine kinase (HK), showing potent antibiofim activity against Staphylococcus epidermidis |
|
| DCC2559 | Hk2 Modulator-1 | Novel allosteric hexokinase 2 (HK2) modulator, selectively detaching HK2 from the mitochondria |
|
| DCC2560 | hl010183 | Novel Metformin Derivative; Inhibitor of Proliferation and Invasion of Triple-Negative Breast Cancer Cells |
|
| DCC2561 | Hl-3-68 | Novel SARS-CoV-2 Main Protease (Mpro) inhibitor, binding to Subsites S1 and S2 (K d =0.69 µM) |
|
| DCC2562 | hla20a | Selective Acetylcholinesterase Inhibitor |
|
| DCC2563 | Hlb-0532247 | Novel phosphoramidate prodrug of ddhCTP, effectively reducing titers of Zika and West Nile viruses in cell culture with minimal nonspecific toxicity to host cells |
|
| DCC2564 | Hlcl-61 | First-in-class inhibitor of protein arginine methyltransferase 5 (PRMT5) |
|
| DCC2565 | Hlö-7 Dimesylate | Novel Nerve Agent Reactivator |
|
| DCC2566 | Hm-50316 | Potent and highly selective FABP4 inhibitor |
|
| DCC2567 | Hm90822 | Novel antagonist to the inhibitors of apoptosis (IAPs), potentiating cell death in EGFR-overexpressing non-small-cell lung cancer cells |
|
| DCC2568 | Hmao-b Inhibitor 5 | Novel highly potent, selective, and competitive hMAO-B inhibitor with high BBB permeability profile and neuroprotective action (IC 50 = 42 nM; SI > 2375) |
|
| DCC2569 | Hmbpp Triammonium Salt | Potent stimulator of gamma delta T cells |
|
| DCC2570 | Hmi-1a3 | Protein kinase C partial agonist, targeting the C1 domain, inhibiting cell proliferation, decreasing cell viability and inducing an apoptotic response |
|
| DCC2571 | Hmk-32 | Irriversible inhibitor of GSK3 |
|
| DCC2572 | Hm-mc4-ppea | Potent inhibitor of nicotinamide phosphoribosyltransferase (Nampt) |
|
| DCC2573 | Hmr1031 | Potent and specific integrin α4ß1 or very late antigen 4 (VLA-4) receptor antagonist, binding to vascular cell adhesion molecule-1 (VCAM-1) and fibronectin |
|
| DCC2574 | Hmr1426 | Novel food intake-reducing agent |
|
